NCT04411550View on ClinicalTrials.gov

Compare Pharmacokinetics, Safety, and Immunogenicity of HLX11 vs. Perjeta in Healthy Chinese Male Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

160

Participants

Timeline

Start Date

July 1, 2020

Primary Completion Date

July 1, 2021

Study Completion Date

July 30, 2021

Conditions

Healthy Male Volunteers

Interventions

DRUG

HLX11

healthy volunteers receive HLX11 (420mg) once

DRUG

CN-Perjeta(Pertuzumab)

healthy volunteers receive CN-Perjeta (420mg) once

DRUG

EU-Perjeta(Pertuzumab)

healthy volunteers receive EU-Perjeta (420mg) once

DRUG

US-Perjeta(Pertuzumab)

healthy volunteers receive US-Perjeta (420mg) once

Trial Locations (1)

Unknown

The Second Hospital of Anhui Medical University, Hefei

All Listed Sponsors

lead

Shanghai Henlius Biotech

INDUSTRY

NCT04411550 - Compare Pharmacokinetics, Safety, and Immunogenicity of HLX11 vs. Perjeta in Healthy Chinese Male Subjects | Biotech Hunter | Biotech Hunter